1. Home
  2. BRLT vs FEMY Comparison

BRLT vs FEMY Comparison

Compare BRLT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.25

Market Cap

20.6M

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

SELL

Current Price

$5.32

Market Cap

21.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BRLT
FEMY
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6M
21.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BRLT
FEMY
Price
$1.25
$5.32
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$1.70
$5.50
AVG Volume (30 Days)
75.1K
1.4M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
$437,483,000.00
$2,293,313.00
Revenue This Year
$6.72
$105.16
Revenue Next Year
$4.95
$200.23
P/E Ratio
N/A
N/A
Revenue Growth
3.63
40.77
52 Week Low
$1.11
$0.29
52 Week High
$3.10
$1.11

Technical Indicators

Market Signals
Indicator
BRLT
FEMY
Relative Strength Index (RSI) 46.09 97.17
Support Level $1.11 $0.47
Resistance Level $1.37 N/A
Average True Range (ATR) 0.06 0.13
MACD 0.00 0.31
Stochastic Oscillator 52.00 83.92

Price Performance

Historical Comparison
BRLT
FEMY

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: